A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease - Olanow, C. Warren; Kieburtz, Karl; Leinonen, Mika; Elmer, Lawrence; Giladi, Nir; Hauser, Robert A.; Klepiskaya, Olga S.; Kreitzman, David L.; Lew, Mark F.; Russell, David S.; Kadosh, Shaul; Litman, Pninit; et al. (Movement disorders, 2017)
Keywords: Activities of daily living; Aged; Antiparkinson Agents - therapeutic use; Benzothiazoles - therapeutic use; Clinical trials; Delayed-Action Preparations; Dopamine receptors; Double-Blind Method; Drug Combinations; Female; Humans; Indans - therapeutic use; Israel; Male; Middle Aged; Motor task performance; Movement disorders; Nausea; Neostriatum; Neurodegenerative diseases; Neuroprotective Agents - therapeutic use; P2B001; Parkinson Disease - drug therapy; Parkinson's disease; Pramipexole; Quality of life; Rasagiline; Severity of Illness Index; Triethylenemelamine; United States; P2B001; Parkinson's disease; Rasagiline; Pramipexole